Wealth Enhancement Advisory Services’s Cytek Biosciences CTKB Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$261K	Buy	62,275 +402	+0.6%	+$1.91K	﹤0.01%	3492
2026 Q2	$222K	Sell	61,873 -10,827	-15%	-$46.2K	﹤0.01%	3494
2026 Q1	$260K	Buy	72,700 +36,975	+103%	+$175K	﹤0.01%	2912
2025 Q4	$202K	Sell	35,725 -650	-2%	-$3.02K	﹤0.01%	3265
2025 Q3	$138K	Buy	36,375 +5,308	+17%	+$19.9K	﹤0.01%	3258
2025 Q2	$117K	Buy	31,067 +15,351	+98%	+$51.2K	﹤0.01%	3115
2025 Q1	$63K	Buy	+15,716	New	+$81.5K	﹤0.01%	2833

Other funds holding CTKB

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Wealth Enhancement Advisory Services's CTKB Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Cytek Biosciences (CTKB) stake by 0.65% in Q3 2026, buying an estimated $1.91K and bringing the position to 62,275 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #3492.

Wealth Enhancement Advisory Services first reported a position in CTKB in Q1 2025 and has held it in 7 quarters since. 20 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

Wealth Enhancement Advisory Services held 62,275 shares of Cytek Biosciences worth $261K as of Q3 2026.
Wealth Enhancement Advisory Services bought 402 Cytek Biosciences shares in Q3 2026, an estimated $1.91K.
Cytek Biosciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3492 holding.
Wealth Enhancement Advisory Services first reported a position in Cytek Biosciences in Q1 2025 and has held it in 7 quarters since.
20 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.